What were the top 5 conclusions from our yearly Life Sciences Executive Briefing?
In preparation of the EPP Life Sciences Pricing forum, the Executive Briefing is a yearly ‘invitation-only’ executive meeting that aims to build a dialogue between CxO’s and industry pricing experts on emerging pricing and commercial topics in the Life Sciences Industry. It was recently organised in Zurich on March 31, 2016.
This discussion platform for no more than 30 of these top professionals in the business creates a one-of-a-kind learning and networking experience.
In short, some hours of thought provoking debate and global best practice at your fingertips.
We have bundled the summaries of the presentations and wrote down the conclusions of the meeting in this document. Read the document here.
These are our top 5 learnings:
- The life sciences industry is a complex adaptive system that is subject to the same evolutionary forces as the natural world.
- Current selection pressures require the industry to adapt to six simultaneous shifts in the business environment.
- The current focus on launch sequencing to mitigate the impact of external reference pricing does not lead to profit optimisation, successful customer engagement or a sustainable business model. It should be ethically responsible, not denying or unduly delaying access to innovative drugs in low-priced markets.
- The challenge of contracting is not to secure reimbursement through discounts, but to obtain volume commitments and drive usage.
- Manufacturers must be willing to walk away from wealthy markets that refuse to make a fair contribution to R&D cost.
Want to read the details? Download the document here.
Want to know more about the 6th EPP Life Sciences Pricing Forum, click here!